Pancreatic Adenocarcinoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | BRCA1 pathogenic variants | Pancreatic Adenocarcinoma | Olaparib | FDA |
| Sensitivity (+) | BRCA2 pathogenic variants | Pancreatic Adenocarcinoma | Olaparib | FDA |
| Sensitivity (+) | v::NRG1 | Pancreatic Adenocarcinoma | Zenocutuzumab | FDA |
| Sensitivity (+) | BRCA1 pathogenic variants | Pancreatic Adenocarcinoma | Olaparib | HC |
| Sensitivity (+) | BRCA2 pathogenic variants | Pancreatic Adenocarcinoma | Olaparib | HC |